5 Key Takeaways

• 1

  Novartis paused eight clinical trials of rapcabtagene autoleucel due to safety concerns after three patients developed serious IEC-HS.

• 2

  All three patients affected by IEC-HS during Novartis trials died, prompting a review of safety data with independent boards.

• 3

  The paused Novartis trials include phase II studies for systemic lupus erythematosus and other autoimmune diseases.

• 4

  Bristol Myers Squibb paused enrollment in trials of zolacabtagene autoleucel after observing transient inflammatory events.

• 5

  Both companies are reviewing safety data while monitoring patients already treated in their respective trials.